Impact of neoadjuvant androgen ablation and other factors on late toxicity after external beam prostate radiotherapy
Mitchell Liu, Jonn Wu, Eric Berthelet(University of British Columbia), Tom Pickles, Mira Keyes(BC Cancer Agency), Howard Pai(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), Alexander Agranovich, Winkle Kwan, Graeme Duncan(BC Cancer Agency), Scott Tyldesley(BC Cancer Agency), James Morris(BC Cancer Agency)
International Journal of Radiation Oncology*Biology*Physics
December 19, 2003
Cited by 82
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532